Myocardial infarction, cerebral infarction, or lower limb arterial or venous thrombosis
Conditions
Interventions
Gold Standard:Myocardial Infarction : Meet the diagnostic criteria established by theWHOor theACC/AHA.
Cerebral Infarction: CTorMRI, meet NIHSS and exclude hemorrhagic stroke
Lower Limb Thrombos:ultr
Index test:Biomarkers:
Serum levels of P-selectin (CD62P),E-selectin (CD62E),Intercellular Adhesion Molecule-1 (ICAM-1
CD54),Vascular Cell Adhesion Molecule-1 (VCAM-1
CD106) Galectin-3 (Gal-3),Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1
CD31,von Willebrand Factor (VWF)
Sponsors
Shandong Provincial Qianfoshan Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Disease group: adult patients (>18 years old) diagnosed with myocardial infarction, cerebral infarction and lower extremity arteriovenous thrombosis, regardless of gender, and meeting the diagnostic criteria of the corresponding diseases (WHO/NINDS/imaging). 2. Inclusion criteria for the control group: age (>18 years), gender is not restricted
Exclusion criteria
Exclusion criteria: 1. Disease group exclusion criteria: (1) Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome) may influence inflammatory responses and adhesion molecule expression. (2) Chronic infectious diseases (e.g., HIV, tuberculosis, chronic hepatitis) may alter adhesion molecule levels through immune activation. (3) Malignant tumours (particularly haematological malignancies or metastatic tumours) may be associated with systemic inflammation or coagulation abnormalities. (4) Severe hepatic or renal dysfunction (e.g., elevated serum creatinine, markedly abnormal transaminase levels) may affect sample metabolism or test accuracy. Concurrent benign colorectal conditions (e.g., ulcerative colitis, colorectal adenomas, polyps) or tumours other than colorectal carcinoma. 2. Exclusion criteria for the control group: tumours; any abnormal findings in complete blood count, urinalysis, blood biochemistry, urine biochemistry, liver/kidney function tests, or blood glucose.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnosis;Diagnosis;Diagnosis;Diagnosis;Diagnosis;Diagnosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Diagnosis; | — |
Countries
China
Contacts
Public ContactXiaohong Shi
Shandong Provincial Qianfoshan Hospital
Outcome results
None listed